Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018
November 06, 2018 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018 Lugano, Switzerland, November 6, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products,...
Helsinn Group strengthens the Board with the appointment of Francesco Granata
October 01, 2018 05:05 ET
|
Helsinn Healthcare S.A.
Helsinn Group strengthens the Board with the appointment of Francesco Granata LUGANO, October 1, 2018: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products,...
Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S.
June 28, 2018 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S. Iselin, NJ, USA, June 28, 2018 – Helsinn Therapeutics (U.S.) Inc., the U.S. subsidiary of...
The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid
June 26, 2018 11:59 ET
|
Helsinn Healthcare S.A.
The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid Lugano, Switzerland, June 26, 2018 – The United...